Triple Negative Breast Cancer technology
A novel and targeted treatment platform in oncology being developed based on new proprietary peptides targeting sortilin receptors. The overexpression of sortilin receptors has been documented in numerous human cancers including ovarian and breast cancers. Targeting sortilin receptors could therefore lead to a selective delivery approach as well as a specific internalization of a number of anticancer agents that can be linked to these peptides.
For more information, visit: www.TheraTech.com